ClinicalTrials.gg
Not yet recruitingNCT06510465NeoURANIAUpdated Jul 19, 2024

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

A Phase 2 interventional study of utidelone and Cisplatin in Breast Cancer, sponsored by RenJi Hospital. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by RenJi Hospital · Phase 2, Interventional, and Treatment

How we know · 9 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing desoxyepothilone B in Breast Neoplasms — 8 open to participants now, 9 under way, 4 of them phase 3. desoxyepothilone B · Breast Neoplasms.

Planned enrollment
6th of 14
143 · median 110
Started
2024
with 2 others
Phase 2
7 of 14
4 open now
Registered
9th of 14
by date
Lead sponsor
1 of 14
RenJi Hospital

Among the 14 studies testing desoxyepothilone B in Breast Neoplasms, this one is the 6th largest by planned enrollment, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 9th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing desoxyepothilone B in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About desoxyepothilone B

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing desoxyepothilone B in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is a prospective, multi-center, single-arm, two-cohort, exploratory study, aiming to explore the effectiveness and safety of neoadjuvant treatment with weekly utidelone combined with cisplatin in breast cancer patients.

Read the detailed description

Explore the effectiveness and safety of neoadjuvant treatment with weekly utidelone combined with cisplatin in high risk early, locally advanced and Inflammatory breast cancer patients.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • utidelone
  • cisplatin
  • neoadjuvant therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old;
  2. Primary invasive breast cancer confirmed by pathology; Before therapy, the primary breast lesion was larger than 2cm(cT2-T4a-d, according to the anatomical staging of AJCC 8th edition), or the clinical images of lymph nodes considered or confirmed metastasis (CN+); or patients whose primary breast lesions are more than 1cm and less than 2cm, and whose lymph nodes have not metastasized (cT1cN0) must meet one of the following conditions: hormone receptor negative, positive, or ki67 greater than 20%. If bilateral breast cancer is found at the same time, it can be admitted to the group, but it is necessary to determine which side of the lesion is to be evaluated before taking the drug;
  3. According to the version 1.1 standard (see Annex I), there is at least one before neoadjuvant therapy;
  4. The score of is 0 or 1;
  5. During neoadjuvant therapy, ovarian function suppression can be given at the same time;
  6. The hematological examination and blood biochemical examination should meet the following requirements: white blood cell count (WBC)≥3.0×109/L, (ANC)≥1.5×109/L and count (PLT) ≥ 75× 109/L; (HB) ≥ 80g/L; Total (TBIL)≤1.5× value (ULN), (sGOT), ALT(sGPT)≤2×ULN and creatinine (Cr) ≤ 1.5× ULN;
  7. rate ≥50mL/min(Cockcroft-Gault formula);
  8. Subjects voluntarily joined the study, signed the form, and had good compliance and cooperated with the follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Patients during pregnancy and lactation, patients with fertility and positive baseline pregnancy test, or women of childbearing age who are unwilling to take effective measures during the whole trial period;
  2. There is distant of breast cancer confirmed by imaging or pathology before enrollment;
  3. There is evidence of sensory or motor nerve diseases;
  4. Severe cardiopulmonary insufficiency, severe hepatic and renal insufficiency, severe concomitant disease or active infection, including known infection;
  5. allergic to the research drug or its auxiliary materials;
  6. Arterial/venous thrombotic events, such as cerebrovascular accident (including ), deep venous thrombosis and pulmonary embolism, occurred within 6 months before the start of the study;
  7. Previous history of other malignant tumors, except the cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and the second primary malignant tumor with high 5-year recurrence-free survival rate determined by researchers;
  8. According to the researcher's judgment, there are accompanying diseases (including but not limited to uncontrollable hypertension, severe diabetes, active infection, thyroid disease, etc.) that seriously endanger the patient's safety or affect the patient's completion of the study, and any other circumstances that the researcher judges that the patient is not suitable for participating in this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
143 participants (estimated)

Study arms

  • Experimental
    HER2 negative breast cancer cohort

    Human Epidermal Growth Factor Receptor 2 (HER2 ) negative breast cancer utidelone and cisplatin

    Drug: utidelone · Drug: Cisplatin

  • Experimental
    HER2 positive breast cancer cohort

    Human Epidermal Growth Factor Receptor 2 (HER2 ) positive breast cancer utidelone,cisplatin,tratuzumab and pertuzumab (both Intravenous preparations or subcutaneous preparations can be used)

    Drug: utidelone · Drug: Cisplatin · Drug: Trastuzumab · Drug: Pertuzumab

Interventions

  • DrugDesoxyepothilone BStudies of Desoxyepothilone BDesoxyepothilone B pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    utidelone 50mg/m2,ivgtt,d1,8,15,22, q28d, up to 4 cycle;

    Also known as: UTD1

  • cisplatin25mg/m2,ivgtt,d1,8,15;q28d, up to 4 cycle.

    Also known as: DDP

  • Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection(Subcutaneous Injection)600mg,subcutaneous Injection,d1,q21d

  • Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase

06

What researchers measure

Primary outcomes

  1. pCR

    ypT0/is ypN0

    Time frame: through surgery completion, an average of 16 weeks

Secondary outcomes

  1. breast pCR

    ypT0/is

    Time frame: through surgery completion, an average of 16 weeks

  2. RCB 0/I rate

    ratio of patients who achieved RCB 0 or RCB I

    Time frame: through surgery completion, an average of 16 weeks

  3. RCB class

    RCB 0, RCB I, RCB II, RCB III

    Time frame: through surgery completion, an average of 16 weeks

  4. Rate of lymph node negative

    ratio of patients who achieved lymph node negative

    Time frame: through surgery completion, an average of 16 weeks

  5. ORR by physical examination

    ratio of patients who achieved complete response or partial response by physical examination

    Time frame: After completing neoadjuvant therapy before surgery, an average of 16 weeks

  6. ORR by MRI

    ratio of patients who achieved complete response or partial response by MRI

    Time frame: After completing neoadjuvant therapy before surgery, an average of 16 weeks

  7. CBR by physical examination

    ratio of patients who achieved complete response or partial response or stable disease by physical examination

    Time frame: After completing neoadjuvant therapy before surgery, an average of 16 weeks

  8. CBR by MRI

    ratio of patients who achieved complete response or partial response or stable disease by MRI

    Time frame: After completing neoadjuvant therapy before surgery, an average of 16 weeks

  9. iDFS

    It is defined as the time from first dose of study intervention administration to the first occurrence of ipsilateral invasive cancer recurrence, contralateral invasive breast cancer, local and/or regional invasive cancer recurrence, distant metastasis or death from any cause.

    Time frame: 2year,3year,5year,8year,10year

  10. EFS

    It is defined as the time from first dose of study intervention administration to the first occurrence of local and/or regional recurrence, contralateral breast cancer, distant metastasis or death from any cause.

    Time frame: 2year,3year,5year,8year,10year

  11. DDFS

    It is defined as the time from first dose of study intervention administration to the first distant metastasis or death from any cause.

    Time frame: 2year,3year,5year,8year,10year

  12. OS

    It is defined as the time from first dose of study intervention administration to death from any cause.

    Time frame: 2year,3year,5year,8year,10year

  13. Quality of Life

    EORTC-QLQ-C30

    Time frame: Through study completion,an average of 1 year

  14. Quality of Life

    EORTC-QLQ-BR23

    Time frame: Through study completion,an average of 1 year

  15. Safety

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: Through study completion,an average of 1 year

  16. Combine with weekly paclitaxel with cispltin in HER2-negative and HER2-positive patients

    Combine with weekly paclitaxel with cispltin in HER2-negative and HER2-positive patients

    Time frame: After completing neoadjuvant therapy before surgery, an average of 16 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Mar 2027, 31 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 31 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2024
First posted
Jul 19, 2024
StartEst.
Aug 1, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2032
Last update
Jul 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06510465
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Jul 19, 2024
Start date
Aug 1, 2024 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
Jul 19, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desoxyepothilone B · Cisplatin

Start the discussion